#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10924	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2128	502.8	0	.	n	.	0	C451T	SNP	451	451	C	674	674	T	583	T,C	461,100	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10924	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2128	502.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1407	1407	C	614	C	593	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20550	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3660	552.7	0	.	n	.	0	T695C	SNP	695	695	T	1034	1034	C	618	C	599	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20550	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3660	552.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2310	2310	C	611	C	584	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20550	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3660	552.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2384	2384	A	620	A	601	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20550	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3660	552.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2936	2936	C	615	C	589	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20550	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3660	552.7	0	HET	.	.	.	A1638G,C	.	1638	1638	A	1977	1977	A	614	A,G,C	344,246,1	.	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1312	folP	855	855	100.0	folP.l6.c30.ctg.1	1600	80.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1088	1090	AGC	121;120;121	A;G;C	117;116;117	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3602	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3346	105.6	1	SNP	p	S91F	1	.	.	271	273	TTC	596	598	TTC	118;118;121	T;T;C	113;112;113	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3602	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3346	105.6	1	SNP	p	G95N	0	.	.	283	285	GGC	608	610	GGC	115;117;119	G;G;C	109;111;111	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3602	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3346	105.6	1	SNP	p	D95G	1	.	.	283	285	GGC	608	610	GGC	115;117;119	G;G;C	109;111;111	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1082	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1342	79.4	1	SNP	p	G45D	0	.	.	133	135	GGC	467	469	GGC	120;120;119	G;G;C	116;116;115	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	526	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	938	55.3	0	.	n	.	0	A197.	DEL	197	197	A	611	611	A	128	A	124	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3648	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2925	122.1	1	SNP	p	D86N	0	.	.	256	258	GAC	562	564	GAC	129;129;133	G;A,C,G;C	122;117,1,1;125	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3648	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2925	122.1	1	SNP	p	R87I	0	.	.	259	261	CGT	565	567	CGT	136;138;138	C;G;T,G	127;132;129,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3648	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2925	122.1	1	SNP	p	R87W	0	.	.	259	261	CGT	565	567	CGT	136;138;138	C;G;T,G	127;132;129,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3648	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2925	122.1	1	SNP	p	S87R	1	.	.	259	261	CGT	565	567	CGT	136;138;138	C;G;T,G	127;132;129,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3648	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2925	122.1	1	SNP	p	S88P	0	.	.	262	264	TCC	568	570	TCC	139;139;137	T,C;C;C	131,1;133;132	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2704	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2655	100.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1608	1610	GGC	115;113;112	G;G;C	109;107;103	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	A311V	0	.	.	931	933	GCC	1294	1296	GCC	184;184;184	G;C;C	176;176;179	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	I312M	1	.	.	934	936	ATG	1297	1299	ATG	183;182;181	A;T;G	174;175;176	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	V316T	1	.	.	946	948	ACC	1309	1311	ACC	184;182;183	A;C;C	173;175;177	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	T316P	0	.	.	946	948	ACC	1309	1311	ACC	184;182;183	A;C;C	173;175;177	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1810	1812	ACC	136;136;134	A;C;C	129;128;125	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1864	1866	GCG	139;140;139	G;C;G	131;135;133	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1864	1866	GCG	139;140;139	G;C;G	131;135;133	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1987	1989	GGT	104;103;101	G;G;T	97;96;91	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1996	1998	AGC	96;95;94	A;G;C	92;90;90	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2383	118.0	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2014	2016	CCG	77;75;76	C,G;C,G;G,C	67,4;65,2;63,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4300	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	3295	128.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1778	1780	CCG	142;145;144	C,G;C,G;G,C	133,2;138,1;135,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1746	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1799	95.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	544	544	C	107	C,G	100,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	S271T	NONSYN	811	813	TCG	49	51	ACT	34;32;30	A;C;T	23;23;23	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	55	57	GAT	27;27;24	G;A;T	24;24;24	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	D276N	NONSYN	826	828	GAT	64	66	AAC	25;25;25	A;A;C	24;25;25	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	N277H	NONSYN	829	831	AAC	67	69	CAC	26;26;26	C;A;C	26;25;26	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	R307E	NONSYN	919	921	AGA	157	159	GAA	11;11;11	G;A;A	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	T311A	NONSYN	931	933	ACA	169	171	GCA	9;9;9	G;C;A	9;9;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	E312D	NONSYN	934	936	GAA	172	174	GAC	10;10;10	G;A;C	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	F314I	NONSYN	940	942	TTC	178	180	ATC	11;11;11	A;T;C	11;11;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	A316S	NONSYN	946	948	GCG	184	186	TCG	10;10;10	T;C;G	9;10;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	V318A	NONSYN	952	954	GTC	190	192	GCC	11;11;11	G;C;C	10;11;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	G319S	NONSYN	955	957	GGC	193	195	AGC	11;11;11	A;G;C	10;10;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	G320A	NONSYN	958	960	GGT	196	198	GCC	11;11;11	G;C;C	10;10;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	166	porB1a	984	222	90.99	porB1a.l15.c30.ctg.1	254	18.4	0	.	p	.	0	G322V	NONSYN	964	966	GGT	202	204	GTT	11;11;11	G;T;T	10;11;10	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1988	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1581	123.5	0	.	p	.	0	G210R	NONSYN	628	630	GGA	883	885	AGA	150;150;150	A;G;A	144;141;143	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1988	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1581	123.5	0	.	p	.	0	S217G	NONSYN	649	651	AGT	904	906	GGT	153;152;151	G;G;T	146;146;143	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1988	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1581	123.5	0	.	p	.	0	G252E	NONSYN	754	756	GGA	1009	1011	GAA	162;161;162	G;A;A	154;154;155	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1988	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1581	123.5	1	SNP	p	G120K	1	.	.	358	360	AAG	613	615	AAG	154;151;148	A,C;A;G,A	142,1;147;136,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1988	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1581	123.5	1	SNP	p	N121D	0	.	.	361	363	AAC	616	618	AAC	150;151;150	A;A;C	144;146;141	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	1988	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	1581	123.5	1	SNP	p	A121N	1	.	.	361	363	AAC	616	618	AAC	150;151;150	A;A;C	144;146;141	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7634	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	4920	152.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	850	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1148	72.4	1	SNP	p	V57M	1	.	.	169	171	ATG	666	668	ATG	167;167;166	A;T;G	158;157;155	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
